News Releases

October 2019

October 28, 2019 10/28/2019 First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes

October 10, 2019 10/10/2019 Working Mother Names Takeda as One of the 2019 100 Best Companies

September 2019

September 25, 2019 9/25/2019 First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

September 24, 2019 9/24/2019 Takeda Announces NATPARA® Special Use Program in the US

September 13, 2019 9/13/2019 Message about the US NATPARA Recall

September 5, 2019 9/5/2019 Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

July 2019

July 22, 2019 7/22/2019 Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

May 2019

May 19, 2019 5/19/2019 New Exploratory Data from VARSITY Study of Vedolizumab Presented at DDW